Aastrom Biosciences RESTORE-CLI trial: Final patient treated Aastrom Biosciences Más.

Aastrom Biosciences’ RESTORE-CLI trial: Final patient treated Aastrom Biosciences, Inc. , a respected developer of autologous cellular treatments for the treatment of severe cardiovascular illnesses, today reported that the final patient offers been treated in the company’s ongoing multi-center, randomized, double-blind, placebo-controlled U.S Más . Phase 2b scientific trial designated RESTORE-CLI. This affected individual received intramuscular injections of either Aastrom’s tissue restoration cells or electrolyte answer for the treatment of vital limb ischemia , the end-stage of peripheral arterial disease.